The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ORKA | +62.55% | +17.35% | +3.25% | +7% |
| S&P | +15.66% | +85.04% | +13.1% | +22% |
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
No news articles found for Oruka Therapeutics.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00K | 0.0% |
| Gross Profit | -$20.00K | 0.0% |
| Market Cap | $930.43M | 3040.1% |
| Market Cap / Employee | $33.23M | 0.0% |
| Employees | 28 | 460.0% |
| Net Income | -$30,277.00K | -5.8% |
| EBITDA | -$34,085.00K | -15.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $91.25M | -77.8% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $1.49M | 77.3% |
| Short Term Debt | $419.00K | 187.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -22.01% | -6.8% |
| Return On Invested Capital | -23.64% | 10.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$21,701.00K | 38.0% |
| Operating Free Cash Flow | -$21,602.00K | 38.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.00 | 1.01 | 1.16 | 2.11 | 132.35% |
| Price to Tangible Book Value | 2.00 | 1.01 | 1.16 | 2.11 | 132.35% |
| Enterprise Value to EBITDA | -13.41 | -3.29 | -5.24 | -14.76 | 3036.11% |
| Return on Equity | -28.2% | -39.1% | -53.1% | -23.0% | 45.10% |
| Total Debt | $968.00K | $947.00K | $2.33M | $1.91M | 93.52% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
